^
    4d
    A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. (PubMed, Cell)
    IGFBP5 knockout or treatment with the IGF1R inhibitor OSI-906 enhances CD8+ T cell infiltration and synergizes with anti-PD1 therapy. Furthermore, this ASCL1-IGFBP5-IGF1R axis and the BVG are conserved across multiple neuroendocrine cancers (NECs). Our findings reveal a previously unrecognized vascular gate in NECs and propose novel therapeutic strategies to enhance immunotherapy efficacy in these recalcitrant cancers.
    Journal
    |
    CD8 (cluster of differentiation 8) • IGF1 (Insulin-like growth factor 1) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
    |
    linsitinib (ASP7487)
    11d
    A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=91, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Sep 2025 | Trial primary completion date: May 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    13d
    Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    paclitaxel • cixutumumab (IMC A12)
    13d
    A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=165, Active, not recruiting, Viridian Therapeutics, Inc. | N=81 --> 165
    Enrollment change
    15d
    Multi-Omics and Machine Learning Analyses Reveal PIK3CG, PRKCD, and TRIM22 as Potential Markers of Poor Prognosis and Immune Activation in Glioblastoma. (PubMed, J Korean Med Sci)
    This study identifies PIK3CG, PRKCD, and TRIM22 as potential biomarkers and therapeutic targets in IDH-wildtype GBM. Their paradoxical association with poor survival and immune activation may inform personalized treatment strategies that combine conventional chemotherapy with immune-based therapies. While our findings are robust across both mixed and IDH-wildtype-focused cohorts, further mechanistic validation is warranted.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • IDH wild-type
    |
    linsitinib (ASP7487) • AGI-6780
    20d
    T-SAFT (Teprotumumab Safety And efficacy in Chinese TAO patients) (ChiCTR2600119191)
    P4, N=30, Shanghai General Hospital; Shanghai General Hospital
    New P4 trial
    |
    Tepezza (teprotumumab-trbw)
    20d
    A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of tiotropium bromide N01 injection in the treatment of newly diagnosed patients with thyroid eye disease who have strabismus (ChiCTR2600118042)
    P=N/A, N=90, The Zhongshan Ophthalmic Center,Sun Yat-sen University; The Zhongshan Ophthalmic Center,Sun Yat-sen University
    New trial
    |
    Tepezza (teprotumumab-trbw)
    1m
    Network pharmacology and in silico docking-based prediction of molecular targets of Pterospermum acerifolium in primary breast cancer and metastases to bones. (PubMed, Comput Biol Chem)
    Interestingly, the molecular docking analyses indicated β-sitosterol to have stronger affinity to ERα, ERβ, IGF1R and VEGFR2 than that of their known inhibitors (tamoxifen, diarylpropionitrile, linsitinib and sorafenib, respectively). Finally, molecular dynamics simulations analyses confirmed strong molecular interactions of β-sitosterol with VEGFR2 and ERβ. Taken together, the findings highlight potential of phytoconstituents of Pterospermum acerifolium, especially β-sitosterol, kaempferol and luteolin, for clinical management of breast cancer and its metastasis to the bone.
    Journal
    |
    KDR (Kinase insert domain receptor) • IGF1R (Insulin-like growth factor 1 receptor)
    |
    sorafenib • tamoxifen • linsitinib (ASP7487)
    1m
    Discovery of novel 2,4-diarylaminopyrimidine derivatives as FAK inhibitors with potent anti-cancer potency. (PubMed, Future Med Chem)
    A series of derivatives (D1-D15) was designed and synthesized by incorporating a hydrazone unit into the TAE-226 scaffold...Mechanistically, compound D12 effectively suppressed FAK phosphorylation and downstream MAPK/ERK and AKT/mTOR signaling, leading to inhibition of colony formation, migration, cell cycle progression, and induction of apoptosis. Compound D12 is a novel FAK inhibitor with improved selectivity and potent antitumor activity, representing a promising lead candidate for cancer therapy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    NVP-TAE226
    1m
    MHB018A Treatment in Patients With Active Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=108, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Trial completion date: Jul 2028 --> Jul 2027 | Trial primary completion date: Jan 2027 --> Jul 2026
    Trial completion date • Trial primary completion date
    1m
    Construction of a novel risk model for esophageal squamous cell carcinoma associated with purinergic signaling pathways and chemoradiotherapy sensitivity genes. (PubMed, Front Med (Lausanne))
    Drugs like VX.702 and BMS.754807 were more effective in the high-risk group...ESCC tumor tissues exhibited markedly decreased AMN and ERICH5 expression but increased HRG compared to normal controls. This study identified prognostic signature genes associated with CRT and PS in ESCC and constructed a risk model that may predict patient survival, which could provide valuable insights for future research on ESCC diagnosis and treatment.
    Journal
    |
    ANXA10 (Annexin A10)
    |
    BMS-754807
    1m
    Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=258, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Jan 2029
    Enrollment open • Trial completion date • Trial primary completion date